SARS-CoV-2 Antibodies Validated with Patient Samples

ProSci offers a comprehensive catalog of SARS-CoV-2 antibodies and recombinant proteins for COVID-19 research representing the entire SARS-CoV-2 proteome.

Featured on this page are SARS-CoV-2 antibodies validated in ELISA and WB, and importantly, validated with patient samples in IHC and IF. Epitope recognition differs within the Spike antibodies, providing latitude in co-localization studies: Cat. No. 3525 recognizes the C-terminal domain of S2, which to date is a conserved sequence in all SARS-CoV viruses; Cat. No. 9083 recognizes the N-terminal domain of SARS-CoV-2 Spike S1; Cat. No. 9087 recognizes Spike RBD.

The sequences of Nucleocapsid, Envelope, and Membrane proteins are to date conserved such that ProSci antibodies for each of these structural proteins provide valuable reagents for viral infectious disease and vaccine research including investigative histopathology. Click to learn more about the interaction of ProSci antibodies with variant SARS-CoV-2 proteins.

In addition, Sun et al. (2021) have developed an IHC protocol focused on the use of 9083 and 9099. "Sensitive and Specific Immunohistochemistry Protocol for Nucleocapsid Protein from All Common SARS-CoV-2 Virus Strains in Formalin-Fixed, Paraffin-Embedded Tissues" Methods Protoc. 2021 10;4(3) 47 PMID: 34287344 (unpublished images). ProSci offers additional antibody methods and protocols used in all our validation studies.

Validated Antibodies against Structural Proteins

Validated Antibodies against Non-structural Proteins